SCHEMBL17487364

SCHEMBL17487364

Nc1ccc2nc(NCc3ccc4cccnc4c3)[nH]c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.47
SMN1; SMN2 Q16637 6/20 0.47
LMNA P02545 3/20 0.47
HTT P42858 3/20 0.47
GFER P55789 1/20 0.47
HIF1A Q16665 1/20 0.47
TP53 P04637 4/20 0.45
MAPT P10636 7/20 0.43
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 2/20 0.43
HSP90AA1 P07900 1/20 0.43
HSP90AB1 P08238 1/20 0.43
TSHR P16473 1/20 0.43
CASP1 P29466 1/20 0.43
ATM Q13315 1/20 0.43
HSD17B10 Q99714 1/20 0.43
NPC1 O15118 4/20 0.43
GAA P10253 3/20 0.43
PKM P14618 3/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17487354 0.80 RAB9A (0.57) RAB9ASMN1; SMN2LMNAHTTGFER
SCHEMBL17487360 0.78 RAB9A (0.45) RAB9ASMN1; SMN2LMNAHTTGFER
SCHEMBL17487324 0.76 RAB9A (0.51) RAB9ASMN1; SMN2LMNAHTTGFER
SCHEMBL17487950 0.76 HDAC6 (0.54) RAB9ASMN1; SMN2LMNAHTTGFER
SCHEMBL17487962 0.76 RAB9A (0.47) RAB9ASMN1; SMN2LMNAHTTGFER
SCHEMBL17488204 0.75 RAB9A (0.53) RAB9ASMN1; SMN2LMNAHTTGFER
SCHEMBL17487313 0.74 HDAC6 (0.64) RAB9ASMN1; SMN2LMNAHTTGFER
SCHEMBL17487663 0.73 RAB9A (0.41) RAB9ASMN1; SMN2LMNAHTTGFER
SCHEMBL18965765 0.73 RAB9A (0.49) RAB9ASMN1; SMN2LMNAHTTGFER
SCHEMBL17488199 0.72 RAB9A (0.56) RAB9ASMN1; SMN2LMNAHTTGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170166563-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS INSTITUT PASTEUR KOREA (KR) 2017-06-15 US disclosed
US-20170166563-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS INSTITUT PASTEUR KOREA (KR) 2017-06-15 US disclosed
WO-2016016421-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS INSTITUT PASTEUR KOREA (KR) 2016-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166563-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS ALOX5, ALOX15, ALOX12 RAB9A 3982/4885SMN1; SMN2 3381/4885LMNA 1905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.